Key result
IVL achieves ~89% procedural success and low one-year major cardiovascular events across all BMI categories.
Why the study?
Evidence on the safety and efficacy of intravascular lithotripsy for calcified coronary lesions in overweight and obese patients remains limited.
Does intravascular lithotripsy have similar safety and efficacy across different body mass index categories in patients with calcified coronary lesions?
Does intravascular lithotripsy have similar safety and efficacy across different body mass index categories in patients with calcified coronary lesions?
Intravascular lithotripsy is a safe and effective strategy for treating calcified coronary lesions regardless of patient BMI, with high procedural success and low complication rates across all weight categories.
Answers are grounded in this paper and cite their sources.
Supports IVL use for calcified lesions independent of BMI; extends real-world evidence across weight categories.
Background Intravascular lithotripsy (IVL) has emerged as an effective treatment for balloon-crossable calcified coronary lesions. However, evidence on the safety and efficacy of IVL in overweight and obese patients remains limited. Methods From the prospective, multicenter BENELUX-IVL registry, conducted across nine hospitals in four European countries, patients undergoing PCI with IVL were selected. Patients were retrospectively stratified into three groups according to body mass index (BMI): normal weight (<25 kg/m²), overweight (25–30 kg/m²), and obese (≥30 kg/m²). The primary efficacy endpoint was procedural success, defined as successful crossing and delivery of IVL pulses across the target lesion, residual stenosis <30% (assessed by QCA), final TIMI 3 flow, and absence of in-hospital major adverse cardiac events (MACE). The primary safety endpoint was the occurrence of in-hospital MACE, including cardiac death, non-fatal myocardial infarction, or target vessel revascularization (TVR). Results Among 514 patients (584 lesions), 36.2% were normal weight (n=186), 41.8% overweight (n=215), and 22.0% obese (n=113). Baseline clinical and angiographic characteristics (age, sex, SYNTAX score, clinical presentation, and angina severity) were comparable across groups. Intraprocedural complications were low and similar among groups (7.5%, 5.6%, and 4.4%, respectively; p=0.93), although a higher rate of hemodynamic instability was observed in the normal weight group (2.1% vs. 0% vs. 0%, p=0.03). Procedural success was high and comparable (88.7%, 88.8%, and 88.5%, respectively; p=0.99). In-hospital MACE occurred infrequently and with no significant differences (1.6%, 2.3%, and 1.8%; p=0.84). At one-year follow-up, MACE rates were 9.1%, 6.5%, and 6.2%, respectively (p=0.48). Conclusions In overweight and obese patients, IVL for the treatment of calcified coronary lesions proved to be a safe and effective strategy, with high procedural success rates and low incidence of device-related adverse events. Larger studies with longer-term follow-up are warranted to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Oliveri et al. (2026) studied this question. Intravascular lithotripsy for calcified coronary lesions achieved high procedural success and low one-year major cardiovascular events across normal weight, overweight, and obese patients.
Synapse has enriched 10 related papers. Consider them for comparative context: